The Russian Archives of Internal Medicine最新文献_第10页

A Clinical Case of Takotsubo Syndrome in the Early Postoperative Period of Rhinoplasty 鼻整形术后早期Takotsubo综合征1例

The Russian Archives of Internal Medicine Pub Date : 2022-07-31 DOI: 10.20514/2226-6704-2022-12-4-316-320

S. Boldueva, V. Feoktistova, D. Evdokimov, A. Kozak, P. V. Lisukova

引用次数: 0

New Diagnostic Possibilities for Determining the Activity of Ulcerative Colitis: The Role of Neutrophils 确定溃疡性结肠炎活动的新诊断可能性:中性粒细胞的作用

The Russian Archives of Internal Medicine Pub Date : 2022-07-31 DOI: 10.20514/2226-6704-2022-12-4-285-292

E. Bolotova, K. Yumukyan, A. Dudnikova

引用次数: 0

Symptoms in the Long Period after the Coronavirus Infection: Results of Long-Term Follow-Up 冠状病毒感染后长期症状:长期随访结果

The Russian Archives of Internal Medicine Pub Date : 2022-07-31 DOI: 10.20514/2226-6704-2022-12-4-302-309

A. V. Melekhov, A. Agaeva, I. Nikitin

{"title":"Symptoms in the Long Period after the Coronavirus Infection: Results of Long-Term Follow-Up","authors":"A. V. Melekhov, A. Agaeva, I. Nikitin","doi":"10.20514/2226-6704-2022-12-4-302-309","DOIUrl":"https://doi.org/10.20514/2226-6704-2022-12-4-302-309","url":null,"abstract":"Background: assessment of type, prevalence and duration of residual symptoms after COVID-19 in recent studies is controversial because of differences in design. Aim: to assess the prevalence and severity of symptoms in the long-term period after COVID-19. Materials and methods: patients hospitalized with COVID-19 in the period 13.04.2020-10.06.2020 were interviewed by phone: 195 (58,2 %) convalescents at 143 (131-154) days after disease onset and 183 (54,6 % ) of them at 340 (325-351) days. Results: The subjective assessment of health status with 100-point scale before and after the COVID-19 was 95 (80-100) and 80 (70-96) points, p< 0,001, at first interview; 90 (80-100) and 80 (60-90) points, p< 0,001, at second one. Various complaints were detected in 63 % of respondents at the first interview and in 75 % at the second, the number of identified symptoms was 2 (0-6) and 4 (1-8) respectively. The most frequent complaints were weakness/fatigue (31.3 and 47.5 % of respondents), joint pain (31.3 and 47.5 %) and dyspnoe/shortness of breath (31.3 and 43.2 %). The growth of these indicators can be associated with a change in the interview methodology. The severity of the symptoms at second interview was low: fatigue — 3 (0-6) points, shortness of breath — 0 (0-3) points; joint pain, weakness and dyspnoe — 0 (0-5) points each. Conclusion: a decrease of health status can sustain for a long time after COVID-19. Symptoms persist in a significant proportion of convalescents, but their severity in the end of follow-up is quite low.","PeriodicalId":176104,"journal":{"name":"The Russian Archives of Internal Medicine","volume":"88 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125510511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Regenerative Therapy for Chronic Heart Failure: Prospects for the Use of Cellular and Acellular Technologies 慢性心力衰竭的再生治疗:细胞和非细胞技术的应用前景

The Russian Archives of Internal Medicine Pub Date : 2022-07-31 DOI: 10.20514/2226-6704-2022-12-4-293-301

I. Dolgopolov, M. Rykov, V. V. Osadchij

{"title":"Regenerative Therapy for Chronic Heart Failure: Prospects for the Use of Cellular and Acellular Technologies","authors":"I. Dolgopolov, M. Rykov, V. V. Osadchij","doi":"10.20514/2226-6704-2022-12-4-293-301","DOIUrl":"https://doi.org/10.20514/2226-6704-2022-12-4-293-301","url":null,"abstract":"Cardiovascular diseases are the second leading cause of death and disability worldwide after malignancies. Heart failure (HF) has a large impact not only on the economics of healthcare but also on the quality of life, functionality and life expectancy of patients. Pharmacological and non-pharmacological therapies have been developed, but these medical therapies have limited effects to cure patients with severe CH. Heart transplantation is limited due to the low number of donor organs. Human cardiac potential for spontaneous repair is insignificant, so regenerative therapy is in great demand as a new treatment strategy. Currently, there are several strategies for heart regeneration. Transplantation of somatic stem cells was safe and modestly improved cardiac function after myocardial infarction and in patients with CF mainly through paracrine mechanisms. Alternatively, new cardiomyocytes could be generated from induced pluripotent stem cells (iPSCs) to transplant into injured hearts. However, several issues remain to be resolved prior to using iPSC-derived cardiomyocytes, such as a potential risk of tumorigenesis and poor survival of transplanted cells in the injured heart. Recently, direct cardiac cell-free reprogramming has emerged as a novel technology to regenerate damaged myocardium by directly converting endogenous cardiac fibroblasts into induced cardiomyocyte-like cells to restore cardiac function. Many researchers have reported direct reprogramming of the heart in vivo in animal and human cells. In this review, we review the current status of cardiac cell-based and cell-free regenerative technology, a great hope to treat cardiovascular diseases in clinical practice.","PeriodicalId":176104,"journal":{"name":"The Russian Archives of Internal Medicine","volume":"60 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127058929","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Acute Osteoporotic Vertebral Fracture. Part 1. Definitions, Clinical Presentation, Pain Assessment, Diagnostic Imaging, Introduction to Differential Diagnosis 急性骨质疏松性椎体骨折。第1部分。定义、临床表现、疼痛评估、诊断影像、鉴别诊断导论

The Russian Archives of Internal Medicine Pub Date : 2022-07-30 DOI: 10.20514/2226-6704-2022-12-4-254-266

V. V. Lyalina, I. A. Borshenko, S. Borisovskaya, E. A. Skripnichenko, R. V. Binyakovskiy, V. Trishina, I. Nikitin

引用次数: 0

Diagnosis and Therapy of Psychosomatic Disorders in Reproductive Cycle of Women in General Medical Practice (Review) 妇女生殖周期心身疾病的诊断与治疗(综述)

The Russian Archives of Internal Medicine Pub Date : 2022-07-30 DOI: 10.20514/2226-6704-2022-12-4-276-284

V. E. Medvedev

引用次数: 0

Prospects for Treatment of Idiopathic Pulmonary Fibrosis 特发性肺纤维化的治疗前景

The Russian Archives of Internal Medicine Pub Date : 2022-07-30 DOI: 10.20514/2226-6704-2022-12-4-267-275

R. Mustafin

{"title":"Prospects for Treatment of Idiopathic Pulmonary Fibrosis","authors":"R. Mustafin","doi":"10.20514/2226-6704-2022-12-4-267-275","DOIUrl":"https://doi.org/10.20514/2226-6704-2022-12-4-267-275","url":null,"abstract":"Idiopathic pulmonary fibrosis (IPF) is a severe, progressive lung disease of unknown etiology with an average worldwide prevalence of 15 per 100,000. According to the etiology, IPF is classified into sporadic, syndromic, and familial cases. Sporadic cases refer to multifactorial diseases and are associated with age, viral infections, smoking and inhalation of dust, contact with chemicals and drugs, gastroesophageal reflux disease. There were revealed an association of sporadic IPF with allelic variants of the genes AKAP13, ATP11A, DPP9, DSP, IVD, IL1RN, FAM13A, MUC5B, SFTPC, SPPL2C, TERC, TERT, TOLLIP. Syndromal IPF develops in German-Pudlak syndrome. Familial cases of the disease are caused by mutations in the genes encoding surfactant (SFTPC), mucin (MUC5B), deadenylation nuclease (PARN), components of telomere functioning (RTEL1, TERC, TERT). In 2000, the American Thoracic Society recommended glucocorticoids and cytostatics for the treatment of ELISA in order to influence the inflammatory process due to the activation of fibroblasts and their accumulation in the extracellular matrix of the lungs. These recommendations are still used by many doctors, despite the publication of reliable data on the increased mortality and hospitalizations of IPF patients taking prednisolone and azathioprine. According to recent meta-analyzes, pirfenidone (an inhibitor of the synthesis of procollagen I and II growth factors) and nintenadib (a tyrosine kinase inhibitor) are the most effective treatments for IPF. Since genetic factors play an important role in the etiopathogenesis of the disease, it is promising to search for methods of targeted therapy for IPF using specific noncoding RNAs as targets, changes in the expression of which are not specific of other bronchopulmonary diseases. These RNAs include miR-9-5p, miR-27b, miR-153, miR-184, miR-326, miR-374, miR-489, miR-630, miR-1343 (decreased expression in IPF); miR-340, miR-424, miR-487b, miR-493, lncRNA AP003419.16, lncRNA AP003419.16 (increased expression in IPF).","PeriodicalId":176104,"journal":{"name":"The Russian Archives of Internal Medicine","volume":"3 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"122611192","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Proton Pump Inhibitors in the COVID-19 Pandemic 质子泵抑制剂在COVID-19大流行中的应用

The Russian Archives of Internal Medicine Pub Date : 2022-07-29 DOI: 10.20514/2226-6704-2022-12-4-245-253

T. Kugler, I. S. Malovichko, V. B. Gnilitskaya, A. L. Khristulenko, N. F. Yarovaya

{"title":"Proton Pump Inhibitors in the COVID-19 Pandemic","authors":"T. Kugler, I. S. Malovichko, V. B. Gnilitskaya, A. L. Khristulenko, N. F. Yarovaya","doi":"10.20514/2226-6704-2022-12-4-245-253","DOIUrl":"https://doi.org/10.20514/2226-6704-2022-12-4-245-253","url":null,"abstract":"The safety of proton pump inhibitors (PPIs) use in coronavirus infection (COVID-19) is not well understood. PPIs are potent suppressors of gastric secretion and become one of the ten most widely used drugs in the world. They are expected to influence virus susceptibility, severity, and outcomes in patients diagnosed with COVID-19. This concern is based on their mechanism of action — suppression of gastric acidity, which is considered the first line of defense against infections. Taken together, the results of most studies and meta-analyses support that PPIs use has been associated with increased risk of COVID-19 and severe outcomes. However, taking into account all potential risk factors for disease severity seems impossible in the real world in the context of COVID-19, so conclusions about causal relationships between PPI use and COVID-19 should be treated with great caution. An additional interesting point about the use of PPIs in the pandemic is that it reduced absorption of certain vitamins. On the other hand, several studies have appeared in the literature regarding the protective therapeutic effects of PPIs. There is growing evidence of an immunomodulatory and antifibrotic role of PPIs that could be used in the treatment of COVID-19. In addition, their ability to alkalize the contents of endosomes and lysosomes serves as an obstacle to the penetration of the virus into host cells. This review analyzes the possible effects of PPIs in patients with COVID-19.","PeriodicalId":176104,"journal":{"name":"The Russian Archives of Internal Medicine","volume":"1 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123045941","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The Course of Alcoholic Cirrhosis of The Liver in a Patient with COVID-19 1例新冠肺炎患者酒精性肝硬化的病程分析

The Russian Archives of Internal Medicine Pub Date : 2022-05-22 DOI: 10.20514/2226-6704-2022-12-3-234-239

E. Kudashkina, L. Ilchenko, I. Fedorov

{"title":"The Course of Alcoholic Cirrhosis of The Liver in a Patient with COVID-19","authors":"E. Kudashkina, L. Ilchenko, I. Fedorov","doi":"10.20514/2226-6704-2022-12-3-234-239","DOIUrl":"https://doi.org/10.20514/2226-6704-2022-12-3-234-239","url":null,"abstract":"This article presents the features of the course of liver cirrhosis (LC) in a patient with a new coronavirus infection. The patient had no specific respiratory symptoms of COVID-19 (CoronaVirus Disease 2019), and the reason for outpatient examination for SARS-CoV-2 (severe acute respiratory syndrome coronavirus) RNA was the presence of these symptoms in relatives. Previously, patient E. had been undergoing in-patient examination and treatment for abdomen volume build-up against the background of prolonged alcoholization, and was diagnosed with alcoholic class B LC according to Child-Pugh classification. Conservative therapy was administered, and the patient was discharged with regression of ascites. Within a week after SARS-CoV-2 identification, patient E. showed signs of LC decompensation in the form of increasing abdominal volume, which required repeated inpatient treatment, during which portal vein thrombosis (PVT) and progression of chronic liver disease (CLD) in the post-coid period were revealed. Literature data on 30-day mortality in patients with LC against COVID-19 background are presented, as well as my own observations on the example of 580 case histories. Complications of new coronavirus infection in patients with CLD, methods of their correction are considered here. This observation demonstrates the social significance of the problem of COVID-19 incidence in patients with LC, the necessity for screening for COVID-19 in case of the presence of decompensation episodes, as well as active prevention of infection in these patients.","PeriodicalId":176104,"journal":{"name":"The Russian Archives of Internal Medicine","volume":"508 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2022-05-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123401203","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pathogenetic Relationship of Immunological Disorders in Chronic Generalized Periodontitis and Rheumatoid Arthritis 慢性广泛性牙周炎与类风湿关节炎免疫功能障碍的发病关系

The Russian Archives of Internal Medicine Pub Date : 2022-05-21 DOI: 10.20514/2226-6704-2022-12-3-203-211

G. V. Poryadin, A. N. Zakhvatov, A. Parshina

引用次数: 0